Ashwin Kishtagari

Ashwin Kishtagari

Auto-generated profile, based on publicly available information

Ashwin Kishtagari

Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Nashville, TN, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2024 in The Journal of Molecular Diagnostics
Verified
Journal Article
Open access
TMTaralynn Mack
Taralynn Mack
CVCaitlyn Vlasschaert
Caitlyn Vlasschaert
KBKelly von Beck
Kelly von Beck
ASAlexander J. Silver
Alexander J. Silver
JHJ. Brett Heimlich
J. Brett Heimlich
ABAlexander G. Bick
Alexander G. Bick
Clonal hematopoiesis of indeterminate potential (CHIP) is a common age-related phenomenon that occurs when hematopoietic stem cells acquire mutations in a select set of genes commonly mutated in myeloid neoplasia which then expand clonally. Current sequencing assays to detect CHIP mutations are not optimized for the detection of these variants and can be cost-prohibitive when applied to large cohorts or serial sequencing. In this study, an affordable (∼$8 per sample), accurate, and scalable sequencing assay for CHIP is introduced and validated. The efficacy of the assay is demonstrated by identifying CHIP mutations in a cohort of 456 individuals with DNA collected at multiple timepoints in the Vanderbilt BioVU biobank and quantifying clonal expansion rates over time. A total of 101 individuals with CHIP/CCUS were identified, and individual-level clonal expansion rate was calculated using the variant allele fraction (VAF) at both timepoints. Differences in clonal expansion rate by driver gene were observed, but there was also significant individual-level heterogeneity, emphasizing the multifactorial nature of clonal expansion. Additionally, the study explores mutation co-occurrence and clonal competition between multiple driver mutations.

16 April 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
CDCourtney Dinardo
Courtney Dinardo
AFAmir Fathi
Amir Fathi
AKAshwin Kishtagari
Ashwin Kishtagari
KBKapil N Bhalla
Kapil N Bhalla
AQAlfonso Quintas-Cardama
Alfonso Quintas-Cardama
ESEytan M. Stein
Eytan M. Stein
Purpose: Safety and preliminary clinical activity of FHD-286, a dual BRG1/BRM (Brahma related gene 1/Brahma homolog) inhibitor, were evaluated in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome. Patients and Methods: In this multicenter, open-label, phase I, dose-escalation study (NCT04891757), patients received FHD-286 orally once daily at 2.5, 5, 7.5, and 10 mg. Results: Forty patients (median age: 65.5 years; 85% with adverse genetic status; and 65% with ≥3 prior therapy lines) received FHD-286 for 28 days (median). FHD-286 was not tolerated at 10 mg once daily. Across all doses, treatment-related adverse events (TRAE) were predominantly grade 1 to 2, most commonly dry mouth (27.5%) and increased alanine aminotransferase (20%). Dose-limiting grade 3 hyperbilirubinemia and grade 3 muscular weakness occurred at 5 and 10 mg once daily, respectively. The most common serious TRAE was differentiation syndrome (DS; 10%). An independent committee retrospectively adjudicated DS in 15% of patients (grade 3 in 5 patients and grade 4 in 1 patient). FHD-286 plasma exposure increased with dose and accumulated with continuous dosing. Exposures were typically higher with concomitant CYP3A4 inhibitors. Myeloid differentiation and leukemic burden reduction were observed across cytogenetic and mutational backgrounds, notably in patients with enhancer-driven genotypes. There were no objective responses. Conclusions: DS was the most frequent serious TRAE. Although antileukemic activity was observed, no objective responses were achieved, and disease progression frequently occurred within 1 to 2 treatment cycles. Blast reductions were reported across cytogenetic and mutational profiles, coupled with myeloid differentiation via BRG1/BRM inhibition. This novel mechanism warrants further investigation of FHD-286 in combination with other agents in myeloid malignancies.

15 January 2024 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
AKAshwin Kishtagari
Ashwin Kishtagari
MKM. A. Wasay Khan
M. A. Wasay Khan
YLYajing Li
Yajing Li
CVCaitlyn Vlasschaert
Caitlyn Vlasschaert
NMNaimisha Marneni
Naimisha Marneni
ABAlexander G. Bick
Alexander G. Bick
Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP and mCAs at the same locus (e.g., transforming a heterozygous JAK2 CHIP mutation into a homozygous mutation through concomitant loss of heterozygosity at chromosome 9) might have important prognostic implications for malignancy transformation risk. We tested this hypothesis using our discovery cohort, the UK Biobank (n = 451,180), and subsequently validated it in the BioVU cohort (n = 91,335). We find that individuals with a concurrent somatic mutation and mCA were at significantly increased risk of hematologic malignancy (for example, In BioVU cohort incidence of hematologic malignancies is higher in individuals with co-occurring JAK2 V617F and 9p CN-LOH; HR = 54.76, 95% CI = 33.92–88.41, P < 0.001 vs. JAK2 V617F alone; HR = 44.05, 95% CI = 35.06–55.35, P < 0.001). Currently, the ‘zygosity’ of the CHIP mutation is not routinely reported in clinical assays or considered in prognosticating CHIP transformation risk. Based on these observations, we propose that clinical reports should include ‘zygosity’ status of CHIP mutations and that future prognostication systems should take mutation ‘zygosity’ into account.

9 December 2024 in British Journal of Haematology
Verified
Journal Article
Open access
THTamanna Haque
Tamanna Haque
ASAditi Shastri
Aditi Shastri
PDPinkal Desai
Pinkal Desai
ZXZhuoer Xie
Zhuoer Xie
DHDanielle Hammond
Danielle Hammond
MSMichael R. Savona
Michael R. Savona
Summary: The age‐associated mutational state of clonal haematopoiesis (CH) is linked to multiple adverse health outcomes. As higher risk CH can lead to progressive neoplastic or vascular disease, there is interest in developing clinical trials to mitigate risk associated with CH. Given the high prevalence of CH, data from clinical trials could have broad public health implications for screening and therapy. Thoughtful consideration is needed to design trials that are both clinically relevant and avoid overmedicalization. Here, we summarize clinical studies of CH to date and provide suggestions and guidance on how to approach designing CH‐focused therapeutic clinical trials. These recommendations are derived from discussions among clinical researchers and scientists emanating from the Inaugural Meeting on Somatic Mutations and Predisease in October 2021.

6 March 2025 in medRxiv
Verified
Preprint
Open access
PDF file
KZKun Zhao
Kun Zhao
YPYash Pershad
Yash Pershad
HPHannah M Poisner
Hannah M Poisner
XMXiaolong Ma
Xiaolong Ma
KQKali Quade
Kali Quade
ABAlexander G Bick
Alexander G Bick
Mosaic chromosomal alterations of the autosomes (aut-mCAs) are large structural somatic mutations which cause clonal hematopoiesis and increase cancer risk. Here, we detected aut-mCAs in 1,011,269 participants across four biobanks. Through integrative analysis of the minimum critical region and inherited genetic variation, we found that proto-oncogenes exclusively drive chromosomal gains, tumor suppressors drive losses, and copy-neutral events can be driven by either. We identified three novel inherited risk loci in CHI3L2, HLA class II, and TERT that modulate aut-mCA risk and ten novel aut-mCA-specific loci. We found specific aut-mCAs are associated with cardiovascular, cerebrovascular, or kidney disease incidence. High-risk aut-mCAs were associated with elevated plasma protein levels of therapeutically actionable targets: NPM1, PARP1, and TACI. Participants with multiple high-risk features such as high clonal fraction, more than one aut-mCA, and abnormal red cell morphology had a 50% cumulative incidence of blood count abnormalities over 2 years. Leveraging inherited variation, we causally established aut-mCAs as premalignant lesions for chronic lymphocytic leukemia. Together, our findings provide a framework integrating somatic mosaicism, germline genetics, and clinical phenotypes to identify individuals who could benefit from preventative interventions.

30 December 2024 in Cancer Discovery
Verified
Journal Article
Open access
JNJinsuke Nishino
Jinsuke Nishino
WHWenhuo Hu
Wenhuo Hu
AKAshwin Kishtagari
Ashwin Kishtagari
BSBo Shen
Bo Shen
XGXiang Gao
Xiang Gao
SMSean J. Morrison
Sean J. Morrison
Peripheral nerves promote mouse bone marrow regeneration by activating β2- and β3-adrenergic receptor signaling, raising the possibility that nonselective β-blockers could inhibit engraftment after hematopoietic cell transplants (HCT). We observed no effect of β-blockers on steady-state mouse hematopoiesis. However, mice treated with a nonselective β-blocker (carvedilol), but not a β1-selective inhibitor (metoprolol), exhibited impaired hematopoietic regeneration after syngeneic or allogeneic HCTs. At two institutions, patients who received nonselective, but not β1-selective, β-blockers after allogeneic HCT exhibited delayed platelet engraftment and reduced survival. This was particularly observed in patients who received posttransplant chemotherapy for graft-versus-host disease prophylaxis, which also accentuated the inhibitory effect of carvedilol on engraftment in mice. In patients who received autologous HCTs, nonselective β-blockers were associated with little or no delay in engraftment. The inhibitory effect of nonselective β-blockers after allogeneic HCT was overcome by transplanting larger doses of hematopoietic cells. Significance: Patients who receive allogeneic HCTs followed by posttransplant chemotherapy for graft-versus-host disease prophylaxis may be at risk of delayed engraftment and increased mortality if administered nonselective β-blockers after transplantation. Transient discontinuation of nonselective β-blockers or transitioning to β1-selective inhibitors after HCT may accelerate engraftment and improve clinical outcomes. See related commentary by Bhatia, p. 666